Chemotherapy for low-grade gliomas: Emerging consensus on its benefits

Neurology

Volumn 68, Issue 21, 2007, Pages 1762-1763

  Wen, Patrick Y ^a   DeAngelis, Lisa M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONSENSUS DEVELOPMENT; DNA METHYLATION; DRUG MECHANISM; DRUG SENSITIVITY; EDITORIAL; ENZYME ACTIVITY; HETEROZYGOSITY LOSS; HUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR GROWTH; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 34249100230     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000266866.13748.a9     Document Type: Editorial

References (15)

1. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 2006;24:1236-1245.
2. Cairncross JC, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-364.
3. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2702-2714.
4. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improve progression-free survival but not overall survival in newly-diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization For Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
5. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific predictors of chemotherapeutic response and survival in patients with oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
6. Buckner JC, Gesme D, Jr. O'Fallon JR, et al. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendrogliomas or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
7. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14:1715-1721.
8. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade-glioma. J Clin Oncol 2003;21:646-651.
9. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
10. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831-1836.
11. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861.
12. Mollermann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
13. Everhard S, Kaloshi G, Criniere, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740-743.
14. Levin N, Lavon I, Fuchs D, et al. Progressive low-grade oligodendrogliomas. Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-1765.
15. Ngo TB, Peng T, Liang XJ, et al. The 1p encoded protein stathmin modulates the resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007 (in press).